Overview
Exenatide is a synthetic version of exendin-4, a naturally occurring peptide found in the venom of the Gila monster lizard. The first GLP-1 receptor agonist approved by the FDA (2005), it shares approximately 50% amino acid homology with human GLP-1. Available as twice-daily Byetta and once-weekly extended-release Bydureon, it remains a foundational treatment for type 2 diabetes.
Mechanism of action
Exenatide binds and activates the glucagon-like peptide-1 receptor (GLP-1R), a G-protein coupled receptor expressed on pancreatic beta cells, gut, brain, heart, and kidneys. Activation triggers glucose-dependent insulin secretion via cAMP-PKA and Epac2 signaling, suppresses inappropriately elevated glucagon from pancreatic alpha cells, and slows gastric emptying—collectively blunting postprandial glucose excursions. Unlike native GLP-1 (half-life ~2 min), exenatide resists degradation by dipeptidyl peptidase-4 (DPP-4) due to an alanine-to-glycine substitution at position 2. Central GLP-1R activation in the hypothalamus and brainstem reduces appetite and increases satiety, contributing to the weight loss observed clinically.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| type 2 diabetes glycemic control (Byetta) | subcutaneous | 5–10 mcg | twice daily | Start at 5 mcg BID for 1 month, then increase to 10 mcg BID if tolerated. Inject 60 minutes before morning and evening meals. |
| type 2 diabetes glycemic control (Bydureon) | subcutaneous | 2–2 mg | once weekly | Fixed dose of 2 mg once weekly. No titration required. Rotate injection site. Extended-release microsphere formulation. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Pivotal AMIGO trials (2004–2005) demonstrated HbA1c reductions of 0.8–1.1% and weight loss of 2–3 kg vs. placebo over 30 weeks in type 2 diabetes. DURATION trials for Bydureon showed HbA1c reduction of ~1.3–1.6% with once-weekly dosing. Unlike some GLP-1 agents, cardiovascular outcome data (EXSCEL trial, 14,752 patients) showed noninferiority but not superiority for major adverse cardiovascular events vs. placebo.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Exenatide for synergistic effects.
Legal status
FDA-approved since April 2005 (Byetta) and January 2012 (Bydureon BCise). Schedule: unscheduled prescription drug. No generic available in the US as of 2026. Indicated for type 2 diabetes mellitus as adjunct to diet and exercise. Off-label use for obesity is common but less prevalent since newer agents (semaglutide, tirzepatide) entered market.
Where to get it
Prescription required
Exenatide is a prescription medication. Consult your healthcare provider or a licensed telehealth platform for access.